The fourth project will bring together an Israeli healthcare company and a Singapore biotech company to find a solution to cure cancer. Israel's Kamedis and Singapore's AP Nutripharm (APN) are working on a topical cream which can help solve some of the common side effects of radiation therapy - a cancer treatment. The two companies are planning to conduct clinical trials at multiple sites with a large number of patients.
SIIRD said the four projects are expected to generate revenues totalling S$250 million (US$206.6 million) in the first three years of commercialisation, involving 60 research scientists and engineers from Singapore and Israel.
Sign up for CIO Asia eNewsletters.